Pioglitazone and PPAR-γmodulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: A national cohort study

Chi Hung Liu, Tsong Hai Lee, Yu Sheng Lin, Pi Shan Sung, Yi Chia Wei, Yan Rong Li

研究成果: Article同行評審

13 引文 斯高帕斯(Scopus)


Background and aim: Peroxisome proliferator-activated receptor-γ(PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are additional benefits from intensive PPAR-γmodulating treatments in Asian patients with T2DM and hypertension (HTN) after IS remains unknown. Methods: Between 2001 and 2013, patients admitted due to IS were identified from the National Health Insurance Research Database of Taiwan. Patients with T2DM and HTN using angiotensin receptor blockers were further included. Eligible patients were divided into two groups: (1) pioglitazone and (2) non-pioglitazone oral anti-diabetic agent groups. Propensity score matching (1:2) was used to balance the distribution of baseline characteristics, stroke severity and medications. The primary outcome was recurrent IS. Subgroup analysis for recurrent IS in pioglitazone and/or telmisartan users, the trend of IS risks across different PPAR-γintensity treatments, and dose-dependent outcomes across different pioglitazone possession ratios were further studied. Statistical significance was set at p < 0.05 and p < 0.1 for clinical outcomes and interaction of subgroup analyses, respectively. Results: There were 3190 and 32,645 patients in the pioglitazone and non-pioglitazone groups. Patients of the pioglitazone group had a lower risk of recurrent IS (subdistribution hazard ratio, 0.91; 95% confidence interval 0.84-0.99). Pioglitazone was also associated with reduced recurrent IS in patients who also used telmisartan (p for interaction = 0.071). A graded correlation was found a borderline significant trend between the intensity of PPAR-γtherapy and following IS (p = 0.076). The dose-dependent outcome also showed that a borderline significant trend that higher pioglitazone possession ratio was associated with a lower risk of recurrent IS (p = 0.068). Conclusions: The current study suggests that the use of pioglitazone in type 2 diabetic and hypertensive IS patients is associated with fewer recurrent IS events in an Asian population. Concurrent telmisartan use or a higher pioglitazone possession ratio may have a trend of increased pleiotropic effects, which could possibly be related to higher PPAR-γeffects. Future studies are warranted to confirm or refute the clinical effects and the possible mechanism of more intensive PPAR-γ-modulating treatments.

期刊Cardiovascular Diabetology
出版狀態Published - 2020 1月 7

All Science Journal Classification (ASJC) codes

  • 內科學
  • 內分泌學、糖尿病和代謝
  • 心臟病學與心血管醫學


深入研究「Pioglitazone and PPAR-γmodulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: A national cohort study」主題。共同形成了獨特的指紋。